@conference{0b5e1629fc8844968b4f4d0cd63f8a85,
title = "Rates and Impact of Combination Immunotherapy with Tumor Treating Fields Therapy in a Glioma Cohort and Proposed Phase II Trial",
author = "Yazmin Odia",
note = "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Tumor-treating fields (TTF) are approved for use in patients with glioblastomas at recurrence (2011) or adjuvant setting (2016) due to survival benefit in various trials. Since 12/2012, 46 patients were treated with TTF for de novo or recurrent gliomas at Columbia University.; AACR ; Conference date: 01-01-2017",
year = "2017",
language = "American English",
}